Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CCR8 | P51685 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5391121 | 0.92 | L3MBTL1 (0.51) | L3MBTL1ATMALDH1A1KDM4ETDP1 | |
| SCHEMBL29450257 | 0.91 | MMP1 (0.54) | L3MBTL1ATMALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL18586177 | 0.91 | MMP1 (0.54) | L3MBTL1ATMALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL1586425 | 0.90 | L3MBTL1 (0.49) | L3MBTL1ATMALDH1A1KDM4ETDP1 | |
| SCHEMBL5408519 | 0.89 | ALDH1A1 (0.53) | L3MBTL1ATMALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL9593679 | 0.88 | MMP1 (0.48) | L3MBTL1ATMALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL3651942 | 0.87 | L3MBTL1 (0.53) | L3MBTL1ATMALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL9581725 | 0.85 | L3MBTL1 (0.55) | L3MBTL1ATMALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL124103 | 0.85 | L3MBTL1 (0.55) | L3MBTL1ATMALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL5385557 | 0.84 | L3MBTL1 (0.50) | L3MBTL1ATMALDH1A1KDM4ESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188266-B1 | Novel piperazine amide derivatives | HOFFMANN LA ROCHE (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-8288541-B2 | Piperazine amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2188266-A2 | NOVEL PIPERAZINE AMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009021868-A2 | NOVEL PIPERAZINE AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-19 | — | — | WO | disclosed |
| US-20090048264-A1 | PIPERAZINE AMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-02-19 | — | — | US | disclosed |
| EP-0703908-A1 | ANALGESIC DIBENZOXAZEPINES AND DIBENZOTHIAZEPINES | G.D. SEARLE & CO. (US) | 1996-04-03 | — | — | EP | disclosed |
| US-5461047-A | Analgesics and treats prostaglandin-E2 mediated diseases in animals | G. D. SEARLE & CO. (US) | 1995-10-24 | — | — | US | disclosed |
| WO-1994029286-A1 | ANALGESIC DIBENZOXAZEPINES AND DIBENZOTHIAZEPINES | G.D. SEARLE & CO. (US) | 1994-12-22 | — | — | WO | disclosed |
| WO-1994027981-A1 | SQUARIC ACID DERIVATIVES OF DIBENZOXAZEPINS OR DIBENZOTHIAZEPINES USEFUL AS ANALGESICS | G.D. SEARLE & CO. (US) | 1994-12-08 | — | — | WO | disclosed |
| US-5354747-A | Analgesics | G. D. SEARLE & CO. (US) | 1994-10-11 | — | — | US | disclosed |
| US-5354746-A | Prostaglandin inhibitor, analgesics | G. D. SEARLE & CO. (US) | 1994-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048264-A1 | PIPERAZINE AMIDE DERIVATIVES | NR1H2, NR1H3, NR1I2 | L3MBTL1 3543/4885ATM 3180/4885ALDH1A1 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.